Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning

Moderna and Merck say their personalized mRNA melanoma vaccine significantly reduced both cancer recurrence and spread in a late-stage trial. The treatment could reach patients as soon as next year if regulators approve it. Reuters reports: Moderna developed the vaccine with Merck and tested it together with immunotherapy drug Keytruda, a widely used treatment for melanoma. [...] This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system